Site Map
Pages
Abstracts
- Matters close to the heart: adaptation of tacrolimus models to inform therapeutic drug monitoring using the PRIOR approach
- An ex vivo study measuring antibiotic adsorption to cardiopulmonary bypass circuitry
- Saliva for TDM of antifungal drugs: voriconazole model
- A mathematical model of CB1 receptor allosteric modulation
- A population pharmacokinetic model of once daily intravenous busulfan in paediatrics characterising time-dependent clearance
- Pharmacokinetic modelling for remdesivir
- A model for procalcitonin concentrations following birth in non infected preterm neonates
- Implementation of a physiologically-based pharmacokinetic modelling approach to evaluate inter-ethnic differences in imatinib dosing regimens
- Toward an in silico viral kinetic model for Covid-19 with pharmacodynamic effects
- A Universal Pharmacokinetic Model for Dexmedetomidine in Children and Adults
- QSP Model Simplification Using Machine Learning with an Application to Heparin Dose-Response in Children
- Extrapolating pharmacokinetic models from adults to neonates and infants: Case studies with paracetamol
- A population pharmacokinetic model of sildenafil in an extra-uterine system for premature lambs
- A model-based evaluation of the effect of bosentan on bile salt disposition in sandwich-cultured human hepatocytes
- Analysis of Laplace Approximation for Pharmaceutical Nonlinear Mixed Effects Models
- Impact of genetic and non-genetic factors on the pharmacokinetics of intravenous immunoglobulin in patients with predominantly antibody deficiencies in Malaysia
- Association between seropositivity and remission in rheumatoid arthritis patients receiving disease-modifying antirheumatic drugs: a retrospective analysis of 5 phase III randomized clinical trials of tocilizumab
- Exploring and optimising the computational efficiency of Inductive Linearisation for estimation
- Issues with virtual populations when applied to nonlinear QSP models
- A quantitative systems pharmacology model for paracetamol overdose and rescue
- Investigating myotoxicity following red-bellied black snake envenomation
- Mechanism-based modelling of meropenem plus tobramycin combination regimens against clinical hypermutable Pseudomonas aeruginosa in the hollow-fibre infection model
- Prediction of multiple-dose relative bioavailability outcome for an extended release valproic acid formulation
- Population Pharmacokinetics Modeling of Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)
- Evaluation of the intact nephron hypothesis using optimal design methodology
- Improved predictive performance using a model averaging algorithm in model-informed precision dosing of vancomycin
- External Evaluation of Vancomycin Models
- Population pharmacokinetics of cefazolin in maternal and umbilical cord sera and target attainment in term neonates
- A Population Pharmacokinetic Model of Linezolid enabling Model-Informed Precision Dosing in Patients with Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis
- Determination of the pharmacodynamics of vancomycin in young infants via time-to-event analysis
- The influence of biologically effective dose (BED) on the 131I therapy response in patients with benign thyroid disease – nonlinear mixed effect modelling approach
- External evaluation of population pharmacokinetic models of tacrolimus in adult heart transplant recipients
- Quantifying the Dose-Response of Unfractionated Heparin Using a System Pharmacology Model of Coagulation
- A Population Pharmacokinetic Model of Phenobarbitone in Neonates to Determine Oral Bioavailability and Facilitate Individualised Dosing
- PBPK modeling for lindane across different species
- Modelling of delivery kinetics of gentamicin administered through umbilical long lines
- A Population Pharmacokinetic Study of Caffeine Citrate in Chinese Premature Neonates
- Future work in Auckland: procalcitonin in healthy and infected neonates to inform PKPD disease progression modelling
- Parameter Analysis for PBPK Model for Enalapril
- Simulations to explore studies of propofol infusions in neonates and infants
- PAGANZ Workshop: CellML and OpenCOR
- Twenty Years of PAGANZ
- How many NMLE articles are published in higher Impact Factor clinical journals?
- Pharmacodynamic effect of evogliptin on bone metabolism in healthy menopausal women
- Combining PK and PD data; a 20 year perspective
- Implementation of an approximate input forcing function for modelling single tissues in the Open Pharmacology Suite
- From the First to the NextDose: My journey through 20 years of PAGANZ
- The Influence of Genotype on Warfarin Dose Predictions
- A Population Pharmacodynamic Study of Apnea of Prematurity and the Effect of Caffeine Citrate in Chinese Premature Neonates
- Evaluation of study designs to test the intact nephron hypothesis
- Analyzing endpoints with many ordered categories: theory and applications
- Predictive performance of a Bayesian forecasting software for tacrolimus in adult heart transplant
- An ePKPD model for sodium nitroprusside in adolescents
- PKPD Explorations Using Paracetamol; 20 years on
- Evaluation of the fingerprint profiles of the cannabinoid-1 receptor signalling via a kinetic modelling approach
- Pharmacometric modelling of deuterium exposure in breastfeeding mother-infant pairs for the determination of exclusive breastfeeding practice
- Investigating the pharmacokinetics of snake venom – a cocktail of toxins
- A mathematical model for warfarin reversal using vitamin K
- A quantitative systems pharmacology model for glutathione depletion during paracetamol overdose
- An extension of Janmahasatian’s fat-free mass model to incorporate differences due to ethnicity
- Dose banding- weighing up benefits vs risks
- A Regression Approach to Visual Predictive Checks for Population Pharmacokinetic and Pharmacodynamic Models
- Vancomycin dose optimisation in patients receiving high-flux haemodialysis
- Mechanism-based modelling to optimise piperacillin plus tobramycin combination dosage regimens against Pseudomonas aeruginosa for patients with altered pharmacokinetics
- Optimal design for determination of AUC with no prior pharmacokinetic knowledge
- A bounded integer model for rating and composite scale data
- Covariate selection methods comparison, introducing the feature of a prior
- Combined population pharmacokinetic model of tenofovir and emtricitabine and their active intracellular metabolites in HIV Patients from the ANRS 134-COPHAR 3 trial
- Meta-analysis of snake venom pharmacokinetics in humans
- Development of a model to predict lean liver volume (LLV) for use in scaling drug clearance
- Assessing the completeness of a QSP model for azathioprine metabolism
- Population pharmacokinetics of gentamicin in paediatrics: quantifying covariate-parameter relationship using the full random effects modelling (FREM) approach
- The Relationship Between Busulphan AUC and the Incidence of Sinusoidal Obstruction Syndrome in Haematopoietic Stem Cell Transplants.
- Study designs for renal drug studies
- Total and unbound mycophenolic acid pharmacokinetics before and after kidney transplantation
- Performance of a Theory-Based Mechanistic Model for Predicting the Target Dose of Warfarin
- ANZDATA: Pharmacology based time to event analysis for death and renal transplant failure
- Pharmacokinetics and metabolism of dabrafenib and trametinib in BRAF V600E/K metastatic melanoma
- A population pharmacokinetic model for 51Cr EDTA to estimate renal function
- Evaluation of assumptions underpinning pharmacometric models
- Kinetic modelling of ligand mediated internalisation
- Linearisation and automatic scale reduction of bone biology QSP models for data-driven analyses
- An approach to evaluating mass and energy balance of pharmacokinetic systems using bond graph theory
- Alphaxalone Anaesthesia PKPD
- Internal Deterministic Identifiability of PK and PKPD Models
- Application of relative forgiveness using clinically observed adherence profiles
- Solutions for nonlinear ordinary differential equations in pharmacokinetic-pharmacodynamic systems
- Population pharmacokinetic and pharmacodynamic properties of OZ439 in healthy volunteers and patients with falciparum and vivax malaria
- NextDose – A web based dosing tool – Development version 2017
- Systems Pharmacology – Learning from GAVamycin
- Performance of estimation methods in modelling the kinetics of respiratory virus infection
- Identifiability analysis of empirical models used for quantifying “biased” ligands
- Population in vitro-in vivo correlation model linking gastrointestinal transit time, pH with the in vivo disposition kinetics of itraconazole
- Assessing the predictive performance of an interactive application to dose adjust voriconazole
- Development of an Interactive Tool to Explore Doses & Sample for Paediatric Trials
- Influence of study design on choice of the allometric exponent
- Improving gentamicin dosing in paediatric oncology patients
- Mechanism-based PK/PD modelling approach to optimise combination dosage regimens against multidrug-resistant clinical isolates of Pseudomonas aeruginosa and in-vivo evaluation in a murine thigh infection model
- Understanding the sensitivity of international normalized ratio (INR) to variations in clotting factor levels
- Population Pharmacokinetic Model of Doxycycline Plasma Concentrations – Pooled Study Data
- Comparison of Non-Compartmental and Mixed Effect Modelling Methods for Establishing Bioequivalence for the Case of Two Compartment Kinetics and Censored Concentrations
- Infliximab maintenance dosing in inflammatory bowel disease: an example for in silico assessment of adaptive dosing strategies
- Busulfan Target Concentration Intervention Audit and Model Evaluation
- Application of an in silico knockout model for gastrointestinal absorption of ketones using a systems pharmacology approach
- A suggestion for determining systematic bias when measuring predictive performance
- Population modelling of influenza viral kinetics, immune response, symptom dynamics and the effect of oseltamivir
- The hazards of acquiring Aspergillus positive culture in children with cystic fibrosis
- The effects of polypharmacy and Drug Burden Index on transitions in cognitive function and death: the CHAMP study
- Population pharmacokinetic modelling of itraconazole and hydroxyl-itraconazole for oral Lozanoc® and Sporanox® capsule formulations in healthy volunteers in fed and fasted state.
- Allopurinol dosing in patients with renal impairment
- Population modelling of lithium in paediatric patients with bipolar disorder: implications for dosing
- Modeling of blood pressure lowering effect for co-administration of valsartan and amlodipine
- Quantitative Assessment of Nocturia Patient’s Urination Pattern and Drug Treatment Effects using a Joint Ordered Categorical Model
- Mechanism-based pharmacodynamic modelling approach to optimise synergistic carbapenem plus aminoglycosides combinations to combat carbapenem-resistant Acinetobacter baumannii
- A repeated time-to-event analysis of onset and offset times of sildenafil erectile response
- Pharmacokinetic modelling of enterohepatic circulation of mycophenolic acid in Malaysian lupus nephritis patients
- Automated proper lumping for the simplification of linear systems
- Impact of high-flux haemodialysis on the probability of target attainment for amoxycillin/clavulanic acid combination therapy
- A Systematic Evaluation of Single Metrics in Discriminating Changes in Rheumatoid Arthritis Disease Activity
- A population PKPD model for neutropenia during Hyper-CVAD chemotherapy in non-Hodgkin lymphoma
- Time-to-event model of leflunomide cessation due to toxicity in rheumatoid arthritis patients: Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with cessation.
- Redefining normal variability of drug disposition
- Characterising the transmission dynamics of Acinetobacter baumannii in intensive care units using hidden Markov models
- Model-based estimation of anticholinergic burden
- Evaluation of NONMEM 7.3.0 and Monolix 4.2.2 by Parametric Bootstrap
- Integrating a PKPD computer simulation in the BPharm course
- SimPharm v2.0: A patient-simulation based clinical pharmacology teaching tool
- The influence of CYP2C9 and VKORC1 genotype on the predictive performance of a Bayesian forecasting method for warfarin therapy
- Model based longitudinal meta-analysis of FEV1 in COPD trials
- The use of a population approach in paraquat toxicokinetic/dynamic study
- Fentanyl for pain management in cancer patients – Population PK design
- Comparing Dosage Adjustment Methods for Once Daily Tobramycin in Children with Cystic Fibrosis
- Population pharmacokinetics of colistin and its prodrug colistin methanesulfonate following intravenous and pulmonary dosing in sheep
- Individualisation of Leflunomide Dosing in Rheumatoid Arthritis Patients : Development of a Semi-Physiologically Based Pharmacokinetic Model
- Oseltamivir dosing optimisation in patients treated with automated peritoneal dialysis
- ISoP Lecture 2014: What have models ever done for you?
- Estimating the relative potencies of an anticholinergic medicine: A methodological view point
- Development of a criterion to quantify forgiveness
- Population pharmacokinetic model for D-β-Hydroxybutyrate following ketone monoester ingestion
- Simplification of a pharmacokinetic model for red blood cell methotrexate disposition
- ISoP Lecture 2013: “Broadening the Impact” – Identifying Some Novel Clinical Applications of Pharmacometrics Research
- Semi-mechanistic PKPD model of thrombocytopenia characterizing the effect of a new histone deacetylase inhibitor (HDACi) in development, in co-administration with doxorubicin.
- Application of Item Response Theory to ADAS-cog Scores Modelling in Alzheimer’s Disease
- Weight-HbA1c-Insulin-Glucose (WHIG) Model for long term disease progression of Type 2 Diabetes
- Modelling analgesia-concentration relationships for morphine in an experimental pain setting
- Pharmacokinetics of Phenobarbitone in Neonates – A Population Model Based on Routine Therapeutic Drug Monitoring Data
- Can literature models describe the neutropenic time course produced by hyper-CVAD chemotherapy in non-Hodgkin lymphoma?
- Exposure-Response Relationship to Assess the Risk of Neutropenia in Patients With Hepatocellular Carcinoma Treated with Tivantinib
- Voriconazole Population Pharmacokinetics
- Application of Population Modelling to Improve the Estimation of Drug Withdrawal Times in Racehorses
- Bayesian Forecasting of Ribavirin in Hepatitis C patients: Population model and validation.
- Mechanism-based modelling and sequential dosing to elucidate subpopulation synergy for antibiotic combinations
- Modeling of glucose absorption
- Identification of continuous covariate relationships
- A Review of Population Pharmacokinetic and Pharmacodynamic Studies of Mycophenolate in Autoimmune Disease Patients
- Population pharmacokinetics of vancomycin in orthopaedic patients
- Identifiability of Population Pharmacokinetic-Pharmacodynamic Models
- Relating intracellular methotrexate polyglutamate concentrations in red blood cells with clinical response in rheumatoid arthritis
- Comparison of the probability of target attainment (PTA) of anidulafungin for antifungal prophylaxis against Candida species
- Evaluation of methods to handle nuisance covariates that are non-ignorable
- Concordance between criteria for covariate model building
- Development of a simplified mathematical model of the human physiome – An application relating to the cardiovascular system
- Investigations of the representation of covariate changes in NONMEM
- Using a Bayesian Modelling Approach with Balanced Informative Prior to Develop a Optimal Paediatric Dosing Paradigm using Scarce PK Data
- Population pharmacokinetic modelling of fentanyl for pain management in cancer patients
- Busulfan pharmacokinetics in neonates, infants, children and adults
- Paracetamol and diclofenac additive effects after tonsillectomy
- Mechanism-based modelling of antibiotics to optimally cure patients and prevent resistance: progress, gaps, and future perspectives
- The design of a pharmacokinetic study of Intranasal Fentanyl
- Treatment of malaria: from drug discovery to optimisation of current therapies.
- Population Modelling of Vildagliptin as an Inhibitor and Substrate of Dipeptidylpeptidase IV and its Effects on Glucagon-Like Peptide 1, Glucose, and Insulin
- Development and application of a pharmacokinetic model for the glycation of albumin
- Optimal designs for pharmacokinetic-pharmacodynamic studies of dihydroartemisinin following oral artesunate
- Mechanism-based population modelling of dihydoartemisinin pharmacodynamics in murine malaria
- Assessment of vancomycin dosing regimens in Intensive Care Unit patients with impaired renal function
- A model for maturation of milrinone clearance from prematurity to adulthood
- Which matrix is the most reliable to judge the inclusion of covariates: reduction of unexplained parameter variability, increase in explained parameter variability or change in OFV?
- Pharmacokinetics of high-dose methotrexate in children with cancer: A mechanism-based evaluation of clearance prediction
- A clinical trial incident: Why simple PK is sometimes not so simple
- Prediction correction: quick fix for VPC misdiagnosis in a tacrolimus popPK model
- A model for fat free mass in humans from very premature neonates to young adults
- NextDose – A web based collaborative tool for dose individualisation
- What is the between cycle variability in methotrexate clearance?
- The pharmacokinetic profile of intravenous paracetamol in adult patients undergoing major abdominal surgery: A population analysis
- A reduction in between subject variability is not mandatory when adding a new covariate
- Evaluation of a Bayesian dose-individualisation method for enoxaparin
- Adaptive PD-optimal design of a pilot study for a clotting time test for enoxaparin
- Dose Correction for the Michaelis-Menten Approximation of the Target – mediated Drug Disposition Model
- Pharmacokinetics of methotrexate in red blood cells
- What is the best dosing regimen for allopurinol in patients with renal impairment?
- Population Pharmacokinetic Analysis of Ropivacaine and its Metabolite PPX from Pooled Data in Neonates, Infants and Children
- Meta-modelling
- Generalisation of T-optimality for discriminating between competing models – an application to paracetamol overdose
- Initial exploration of numerical methods for fitting models to PK data
- Design of pharmacokinetic studies for latent covariates
- Development of a Mechanism-Based Model for the Pharmacodynamics of Daptomycin against Methicillin Resistant Staphylococcus aureus (MRSA)
- The effect of surgery on the glucuronidation and sulphation of paracetamol
- Modelling red blood cell data
- Utilising prior literature population models to inform clinical practice – a dosing regimen for immediate N-acetyl cysteine treatment of paracetamol overdose
- Identification and initial evaluation of a prototype clotting time test for enoxaparin
- Antibiotic Dosing Calculator in Neonates and Children Trial
- Population Pharmacokinetics of Paracetamol in Overdose in a Single Patient
- Dexmedetomidine Hemodynamics in Children after Cardiac Surgery
- Modeling of non-stationary RBC survival: Effect of erythropoietin on RBC mortality vs. production in rats.
- Quantifying Disease Progress with Inactive Treatments in Multiple Parkinson
- Methods to Determine Optimal Sampling Windows for Nonlinear Mixed Effects Models
- Optimal designs for population pharmacokinetic studies of the partner drugs administered with artemisinin derivatives
- Development of fluconazole dosage guidelines in critically ill patients receiving continuous venovenous hemodiafiltration
- fit4NM : A tool for NONMEM users
- The use of PKPD simulations to inform the rational use of medicines in clinical practice: the case of simvastatin circadian dosing
- What is needed for a dosing calculator?
- Predicting Weight Using Postmenstrual Age
- Is Morphine Clearance Predictable in Humans?
- Missing data
- Population Pharmacokinetic-Pharmacodynamic Modeling: When Modeling Meets Reality
- Population pharmacokinetics of midazolam in critically ill septic patients
- Population pharmacokinetic and pharmacodynamics analysis of lipid emulsion propofol in pediatric patients
- Population Pharmacokinetics of Gentamicin in Saudi Newborns during the 1st Week of Life
- Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically-Ill Patients from a Multi-Center Study Provide Dosing Recommendations for Patients
- Missing data – the problem of silent evidence
- Statisticians and Pharmacometricians: What can they learn from each other?
- Population pharmacokinetics of meropenem in burn patients
- Pharmacodynamics of venlafaxine in overdose
- Identifiability of random effects parameters in mixed effects models
- Adaptive Bridging Studies in Pharmacokinetics
- Online dose calculation tool for determining dosing regimens in the very young
- Predicting the antimalarial effect of artesunate-mefloquine combination therapy using a mechanistic pharmacokinetic-pharmacodynamic model
- Optimal designs for warfarin INR monitoring
- A mathematical model for the effect of malaria on arginine catabolism in endothelial cells
- Population Pharmacokinetics of Vancomycin in Premature Malaysian Neonates: Identification of Predictors for Dosing Determination in the First Month of Life
- Evaluation of an optimal design for examining melphalan pharmacokinetics in patients with multiple myeloma
- A population PK-PD model of unbound Docetaxel in patients with liver impairment and identification of potential covariates for initial dosage adjustment
- Design of survival studies for red blood cells
- Optimal design of time-to-event models with an emphasis on dropouts in disease progression studies
- Population pharmacokinetics of total and unbound melphalan in patients with multiple myeloma
- Developing a model for estimating lean body weight in children
- Can PBPK Models Predict Post-Mortem Redistribution?
- Pharmacokinetics of Tramadol in Human Neonates, Children and Adults and in Adult Rats, Cats, Dogs, Goats and Horses
- Population pharmacokinetics of oxypurinol in patients with gout receiving allopurinol
- Optimal designs for population pharmacokinetic studies of a drug with large assay variability for patients with restrictive sampling schedules
- Novel diagnostics for assessing fit of logistic regression models
- The population pharmacokinetics of propofol: a meta-analysis of studies available from the OpenTCI Initiative
- Pharmacokinetics of Chloroquine in Pregnant and Non-pregnant Women in Papua New Guinea
- The Influence of Study Design on Identification of True Parameter-Covariate Relationships
- Risk of QTc Interval Prolongation and Torsades de Pointes (TdP) with Amisulpride
- A nonlinear mixed effects model to characterise lamivudine absorption and distribution
- The Effect of Study Design on Pharmacokinetics in Patients with Impaired Renal Function
- Does the use of Lean Body Weight (LBW) in a modified Cockcroft-Gault (C-G) equation provide a better prediction of gentamicin clearance?
- Understanding intranasal fentanyl for acute pain treatment in children: randomized controlled trials or population pharmacodynamic studies?
- Non Linear Deconvolution
- Robust D-optimal Design of Nonlinear Fixed Effects Pharmacokinetic Model
- Population pharmacokinetics of mycophenolic acid in children and young people undergoing bone marrow and solid organ transplantation
- Correlation in the absorption of lamivudine and zidovudine when administered as a fixed-dose combination tablet
- A case for routine monitoring of enoxaparin treatment
- Recirculatory Modelling of Nasal Fentanyl in Man
- Pharmacokinetics of Ethanol in the Presence of Methanol
- Population Pharmacokinetics Of Gentamicin In Very Premature Neonates
- An assessment of methods for modelling regional pharmacokinetics – pooled data, pooled parameter estimates or NONMEM?
- Mechanism-based Pharmacodynamic (PD) Modeling of Phenotypic Tolerance in Pseudomonas aeruginosa for Ceftazidime
- Lean body weight versus total body weight for propofol dosing
- A model of coagulation disturbances in snake bites
- Population pharmacokinetics of phenobarbitone administered as oral rescue therapy in children with refractory status epilepticus
- The evaluation of an individualised dosing strategy derived from population PK modelling and simulation
- Lean Body Weight as a Robust Size Descriptor for Quantifying the Impact of Body Composition on Drug Clearance
- Handling Correlated Variables
- Population pharmacokinetics of acyclovir in children with malignancy
- What to do about missing dosage history?
- Optimal design for drug interaction studies – Beyond the criss-cross design
- Modeling Diverse Anti-Diabetic Drug Effects Using Indirect Response Models: Review
- Simulation of an optimal pharmacokinetic and pharmacodynamic amikacin dosing regimen for neonates
- Mechanistic Modeling of Magnetically Marked Extended Release Formulation of Felodipine
- Handling data below the limit of quantification in mixed effect models
- When Missing Does Not Mean Lost [OED]
- Population pharmacokinetics of melphalan in myeloma patients undergoing an autograft
- Pharmacokinetics of L-arginine after intravenous infusion in adults with moderately severe malaria
- Preclinical Population PK/PD of TGF beta RI Kinase inhibitor for Cancer
- Lean Body Weight versus Total Body Weight as a Covariate for Clearance
- Normalized prediction distribution errors for the evaluation of nonlinear mixed-models
- Tobramycin in paediatric CF patients – TCI or
- Development of a sufficient design for parameter estimation of fluconazole population pharmacokinetics in HIV patients
- Population pharmacokinetic analysis of morphine in opioid dependent and control subjects
- Comparison of different diagnostic criterion to evaluate nonlinear mixed-effects models
- Optimal Designs of Studying Bioimpedance – Design for Nonlinear Mixed Effects Models
- Nonlinear Mixed Effects Modeling of the Steady-State Pharmacokinetics (PK) of Tipranavir/Ritonavir 500/200 mg bid (TPV/r) for Adult Healthy Volunteers and HIV+ Patients
- Different ways of incorporating data below the quantification limit in datasets for parameter estimation
- Population Pharmacokinetics of Amikacin in Very Premature Malaysian Neonates
- Maximum likelihood estimation in nonlinear mixed effects models with the SAEM algorithm
- Population Pharmacokinetics of Oral and Intravenous Caffeine in Extremely Premature Neonates
- Population Pharmacokinetics of Phase 1/2a Data After Oral Tablet Administration of Maraviroc
Uncategorized
- Matters close to the heart: adaptation of tacrolimus models to inform therapeutic drug monitoring using the PRIOR approach
- An ex vivo study measuring antibiotic adsorption to cardiopulmonary bypass circuitry
- Saliva for TDM of antifungal drugs: voriconazole model
- A mathematical model of CB1 receptor allosteric modulation
- A population pharmacokinetic model of once daily intravenous busulfan in paediatrics characterising time-dependent clearance
- Pharmacokinetic modelling for remdesivir
- A model for procalcitonin concentrations following birth in non infected preterm neonates
- Implementation of a physiologically-based pharmacokinetic modelling approach to evaluate inter-ethnic differences in imatinib dosing regimens
- Toward an in silico viral kinetic model for Covid-19 with pharmacodynamic effects
- A Universal Pharmacokinetic Model for Dexmedetomidine in Children and Adults
- QSP Model Simplification Using Machine Learning with an Application to Heparin Dose-Response in Children
- Extrapolating pharmacokinetic models from adults to neonates and infants: Case studies with paracetamol
- A population pharmacokinetic model of sildenafil in an extra-uterine system for premature lambs
- A model-based evaluation of the effect of bosentan on bile salt disposition in sandwich-cultured human hepatocytes
- Analysis of Laplace Approximation for Pharmaceutical Nonlinear Mixed Effects Models
- Impact of genetic and non-genetic factors on the pharmacokinetics of intravenous immunoglobulin in patients with predominantly antibody deficiencies in Malaysia
- Association between seropositivity and remission in rheumatoid arthritis patients receiving disease-modifying antirheumatic drugs: a retrospective analysis of 5 phase III randomized clinical trials of tocilizumab
- Exploring and optimising the computational efficiency of Inductive Linearisation for estimation
- Issues with virtual populations when applied to nonlinear QSP models
- A quantitative systems pharmacology model for paracetamol overdose and rescue
- Investigating myotoxicity following red-bellied black snake envenomation
- Mechanism-based modelling of meropenem plus tobramycin combination regimens against clinical hypermutable Pseudomonas aeruginosa in the hollow-fibre infection model
- Prediction of multiple-dose relative bioavailability outcome for an extended release valproic acid formulation
- Population Pharmacokinetics Modeling of Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)
- Evaluation of the intact nephron hypothesis using optimal design methodology
- Improved predictive performance using a model averaging algorithm in model-informed precision dosing of vancomycin
- External Evaluation of Vancomycin Models
- Population pharmacokinetics of cefazolin in maternal and umbilical cord sera and target attainment in term neonates
- A Population Pharmacokinetic Model of Linezolid enabling Model-Informed Precision Dosing in Patients with Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis
- Determination of the pharmacodynamics of vancomycin in young infants via time-to-event analysis
- The influence of biologically effective dose (BED) on the 131I therapy response in patients with benign thyroid disease – nonlinear mixed effect modelling approach
- External evaluation of population pharmacokinetic models of tacrolimus in adult heart transplant recipients
- Quantifying the Dose-Response of Unfractionated Heparin Using a System Pharmacology Model of Coagulation
- A Population Pharmacokinetic Model of Phenobarbitone in Neonates to Determine Oral Bioavailability and Facilitate Individualised Dosing
- PBPK modeling for lindane across different species
- Modelling of delivery kinetics of gentamicin administered through umbilical long lines
- A Population Pharmacokinetic Study of Caffeine Citrate in Chinese Premature Neonates
- Future work in Auckland: procalcitonin in healthy and infected neonates to inform PKPD disease progression modelling
- Parameter Analysis for PBPK Model for Enalapril
- Simulations to explore studies of propofol infusions in neonates and infants
- PAGANZ Workshop: CellML and OpenCOR
- Twenty Years of PAGANZ
- How many NMLE articles are published in higher Impact Factor clinical journals?
- Pharmacodynamic effect of evogliptin on bone metabolism in healthy menopausal women
- Combining PK and PD data; a 20 year perspective
- Implementation of an approximate input forcing function for modelling single tissues in the Open Pharmacology Suite
- From the First to the NextDose: My journey through 20 years of PAGANZ
- The Influence of Genotype on Warfarin Dose Predictions
- A Population Pharmacodynamic Study of Apnea of Prematurity and the Effect of Caffeine Citrate in Chinese Premature Neonates
- Evaluation of study designs to test the intact nephron hypothesis
- Analyzing endpoints with many ordered categories: theory and applications
- Predictive performance of a Bayesian forecasting software for tacrolimus in adult heart transplant
- An ePKPD model for sodium nitroprusside in adolescents
- PKPD Explorations Using Paracetamol; 20 years on
- Evaluation of the fingerprint profiles of the cannabinoid-1 receptor signalling via a kinetic modelling approach
- Pharmacometric modelling of deuterium exposure in breastfeeding mother-infant pairs for the determination of exclusive breastfeeding practice
- Investigating the pharmacokinetics of snake venom – a cocktail of toxins
- A mathematical model for warfarin reversal using vitamin K
- A quantitative systems pharmacology model for glutathione depletion during paracetamol overdose
- An extension of Janmahasatian’s fat-free mass model to incorporate differences due to ethnicity
- Dose banding- weighing up benefits vs risks
- A Regression Approach to Visual Predictive Checks for Population Pharmacokinetic and Pharmacodynamic Models
- Vancomycin dose optimisation in patients receiving high-flux haemodialysis
- Mechanism-based modelling to optimise piperacillin plus tobramycin combination dosage regimens against Pseudomonas aeruginosa for patients with altered pharmacokinetics
- Optimal design for determination of AUC with no prior pharmacokinetic knowledge
- A bounded integer model for rating and composite scale data
- Covariate selection methods comparison, introducing the feature of a prior
- Combined population pharmacokinetic model of tenofovir and emtricitabine and their active intracellular metabolites in HIV Patients from the ANRS 134-COPHAR 3 trial
- Meta-analysis of snake venom pharmacokinetics in humans
- Development of a model to predict lean liver volume (LLV) for use in scaling drug clearance
- Assessing the completeness of a QSP model for azathioprine metabolism
- Population pharmacokinetics of gentamicin in paediatrics: quantifying covariate-parameter relationship using the full random effects modelling (FREM) approach
- The Relationship Between Busulphan AUC and the Incidence of Sinusoidal Obstruction Syndrome in Haematopoietic Stem Cell Transplants.
- Study designs for renal drug studies
- Total and unbound mycophenolic acid pharmacokinetics before and after kidney transplantation
- Performance of a Theory-Based Mechanistic Model for Predicting the Target Dose of Warfarin
- ANZDATA: Pharmacology based time to event analysis for death and renal transplant failure
- Pharmacokinetics and metabolism of dabrafenib and trametinib in BRAF V600E/K metastatic melanoma
- A population pharmacokinetic model for 51Cr EDTA to estimate renal function
- Evaluation of assumptions underpinning pharmacometric models
- Kinetic modelling of ligand mediated internalisation
- Linearisation and automatic scale reduction of bone biology QSP models for data-driven analyses
- An approach to evaluating mass and energy balance of pharmacokinetic systems using bond graph theory
- Alphaxalone Anaesthesia PKPD
- Internal Deterministic Identifiability of PK and PKPD Models
- Application of relative forgiveness using clinically observed adherence profiles
- Solutions for nonlinear ordinary differential equations in pharmacokinetic-pharmacodynamic systems
- Population pharmacokinetic and pharmacodynamic properties of OZ439 in healthy volunteers and patients with falciparum and vivax malaria
- NextDose – A web based dosing tool – Development version 2017
- Systems Pharmacology – Learning from GAVamycin
- Performance of estimation methods in modelling the kinetics of respiratory virus infection
- Identifiability analysis of empirical models used for quantifying “biased” ligands
- Population in vitro-in vivo correlation model linking gastrointestinal transit time, pH with the in vivo disposition kinetics of itraconazole
- Assessing the predictive performance of an interactive application to dose adjust voriconazole
- Development of an Interactive Tool to Explore Doses & Sample for Paediatric Trials
- Influence of study design on choice of the allometric exponent
- Improving gentamicin dosing in paediatric oncology patients
- Mechanism-based PK/PD modelling approach to optimise combination dosage regimens against multidrug-resistant clinical isolates of Pseudomonas aeruginosa and in-vivo evaluation in a murine thigh infection model
- Understanding the sensitivity of international normalized ratio (INR) to variations in clotting factor levels
- Population Pharmacokinetic Model of Doxycycline Plasma Concentrations – Pooled Study Data
- Comparison of Non-Compartmental and Mixed Effect Modelling Methods for Establishing Bioequivalence for the Case of Two Compartment Kinetics and Censored Concentrations
- Infliximab maintenance dosing in inflammatory bowel disease: an example for in silico assessment of adaptive dosing strategies
- Busulfan Target Concentration Intervention Audit and Model Evaluation
- Application of an in silico knockout model for gastrointestinal absorption of ketones using a systems pharmacology approach
- A suggestion for determining systematic bias when measuring predictive performance
- Population modelling of influenza viral kinetics, immune response, symptom dynamics and the effect of oseltamivir
- The hazards of acquiring Aspergillus positive culture in children with cystic fibrosis
- The effects of polypharmacy and Drug Burden Index on transitions in cognitive function and death: the CHAMP study
- Population pharmacokinetic modelling of itraconazole and hydroxyl-itraconazole for oral Lozanoc® and Sporanox® capsule formulations in healthy volunteers in fed and fasted state.
- Allopurinol dosing in patients with renal impairment
- Population modelling of lithium in paediatric patients with bipolar disorder: implications for dosing
- Modeling of blood pressure lowering effect for co-administration of valsartan and amlodipine
- Quantitative Assessment of Nocturia Patient’s Urination Pattern and Drug Treatment Effects using a Joint Ordered Categorical Model
- Mechanism-based pharmacodynamic modelling approach to optimise synergistic carbapenem plus aminoglycosides combinations to combat carbapenem-resistant Acinetobacter baumannii
- A repeated time-to-event analysis of onset and offset times of sildenafil erectile response
- Pharmacokinetic modelling of enterohepatic circulation of mycophenolic acid in Malaysian lupus nephritis patients
- Automated proper lumping for the simplification of linear systems
- Impact of high-flux haemodialysis on the probability of target attainment for amoxycillin/clavulanic acid combination therapy
- A Systematic Evaluation of Single Metrics in Discriminating Changes in Rheumatoid Arthritis Disease Activity
- A population PKPD model for neutropenia during Hyper-CVAD chemotherapy in non-Hodgkin lymphoma
- Time-to-event model of leflunomide cessation due to toxicity in rheumatoid arthritis patients: Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with cessation.
- Redefining normal variability of drug disposition
- Characterising the transmission dynamics of Acinetobacter baumannii in intensive care units using hidden Markov models
- Model-based estimation of anticholinergic burden
- Evaluation of NONMEM 7.3.0 and Monolix 4.2.2 by Parametric Bootstrap
- Integrating a PKPD computer simulation in the BPharm course
- SimPharm v2.0: A patient-simulation based clinical pharmacology teaching tool
- The influence of CYP2C9 and VKORC1 genotype on the predictive performance of a Bayesian forecasting method for warfarin therapy
- Model based longitudinal meta-analysis of FEV1 in COPD trials
- The use of a population approach in paraquat toxicokinetic/dynamic study
- Fentanyl for pain management in cancer patients – Population PK design
- Comparing Dosage Adjustment Methods for Once Daily Tobramycin in Children with Cystic Fibrosis
- Population pharmacokinetics of colistin and its prodrug colistin methanesulfonate following intravenous and pulmonary dosing in sheep
- Individualisation of Leflunomide Dosing in Rheumatoid Arthritis Patients : Development of a Semi-Physiologically Based Pharmacokinetic Model
- Oseltamivir dosing optimisation in patients treated with automated peritoneal dialysis
- ISoP Lecture 2014: What have models ever done for you?
- Estimating the relative potencies of an anticholinergic medicine: A methodological view point
- Development of a criterion to quantify forgiveness
- Population pharmacokinetic model for D-β-Hydroxybutyrate following ketone monoester ingestion
- Simplification of a pharmacokinetic model for red blood cell methotrexate disposition
- ISoP Lecture 2013: “Broadening the Impact” – Identifying Some Novel Clinical Applications of Pharmacometrics Research
- Semi-mechanistic PKPD model of thrombocytopenia characterizing the effect of a new histone deacetylase inhibitor (HDACi) in development, in co-administration with doxorubicin.
- Application of Item Response Theory to ADAS-cog Scores Modelling in Alzheimer’s Disease
- Weight-HbA1c-Insulin-Glucose (WHIG) Model for long term disease progression of Type 2 Diabetes
- Modelling analgesia-concentration relationships for morphine in an experimental pain setting
- Pharmacokinetics of Phenobarbitone in Neonates – A Population Model Based on Routine Therapeutic Drug Monitoring Data
- Can literature models describe the neutropenic time course produced by hyper-CVAD chemotherapy in non-Hodgkin lymphoma?
- Exposure-Response Relationship to Assess the Risk of Neutropenia in Patients With Hepatocellular Carcinoma Treated with Tivantinib
- Voriconazole Population Pharmacokinetics
- Application of Population Modelling to Improve the Estimation of Drug Withdrawal Times in Racehorses
- Bayesian Forecasting of Ribavirin in Hepatitis C patients: Population model and validation.
- Mechanism-based modelling and sequential dosing to elucidate subpopulation synergy for antibiotic combinations
- Modeling of glucose absorption
- Identification of continuous covariate relationships
- A Review of Population Pharmacokinetic and Pharmacodynamic Studies of Mycophenolate in Autoimmune Disease Patients
- Population pharmacokinetics of vancomycin in orthopaedic patients
- Identifiability of Population Pharmacokinetic-Pharmacodynamic Models
- Relating intracellular methotrexate polyglutamate concentrations in red blood cells with clinical response in rheumatoid arthritis
- Comparison of the probability of target attainment (PTA) of anidulafungin for antifungal prophylaxis against Candida species
- Evaluation of methods to handle nuisance covariates that are non-ignorable
- Concordance between criteria for covariate model building
- Development of a simplified mathematical model of the human physiome – An application relating to the cardiovascular system
- Investigations of the representation of covariate changes in NONMEM
- Using a Bayesian Modelling Approach with Balanced Informative Prior to Develop a Optimal Paediatric Dosing Paradigm using Scarce PK Data
- Population pharmacokinetic modelling of fentanyl for pain management in cancer patients
- Busulfan pharmacokinetics in neonates, infants, children and adults
- Paracetamol and diclofenac additive effects after tonsillectomy
- Mechanism-based modelling of antibiotics to optimally cure patients and prevent resistance: progress, gaps, and future perspectives
- The design of a pharmacokinetic study of Intranasal Fentanyl
- Treatment of malaria: from drug discovery to optimisation of current therapies.
- Population Modelling of Vildagliptin as an Inhibitor and Substrate of Dipeptidylpeptidase IV and its Effects on Glucagon-Like Peptide 1, Glucose, and Insulin
- Development and application of a pharmacokinetic model for the glycation of albumin
- Optimal designs for pharmacokinetic-pharmacodynamic studies of dihydroartemisinin following oral artesunate
- Mechanism-based population modelling of dihydoartemisinin pharmacodynamics in murine malaria
- Assessment of vancomycin dosing regimens in Intensive Care Unit patients with impaired renal function
- A model for maturation of milrinone clearance from prematurity to adulthood
- Which matrix is the most reliable to judge the inclusion of covariates: reduction of unexplained parameter variability, increase in explained parameter variability or change in OFV?
- Pharmacokinetics of high-dose methotrexate in children with cancer: A mechanism-based evaluation of clearance prediction
- A clinical trial incident: Why simple PK is sometimes not so simple
- Prediction correction: quick fix for VPC misdiagnosis in a tacrolimus popPK model
- A model for fat free mass in humans from very premature neonates to young adults
- NextDose – A web based collaborative tool for dose individualisation
- What is the between cycle variability in methotrexate clearance?
- The pharmacokinetic profile of intravenous paracetamol in adult patients undergoing major abdominal surgery: A population analysis
- A reduction in between subject variability is not mandatory when adding a new covariate
- Evaluation of a Bayesian dose-individualisation method for enoxaparin
- Adaptive PD-optimal design of a pilot study for a clotting time test for enoxaparin
- Dose Correction for the Michaelis-Menten Approximation of the Target – mediated Drug Disposition Model
- Pharmacokinetics of methotrexate in red blood cells
- What is the best dosing regimen for allopurinol in patients with renal impairment?
- Population Pharmacokinetic Analysis of Ropivacaine and its Metabolite PPX from Pooled Data in Neonates, Infants and Children
- Meta-modelling
- Generalisation of T-optimality for discriminating between competing models – an application to paracetamol overdose
- Initial exploration of numerical methods for fitting models to PK data
- Design of pharmacokinetic studies for latent covariates
- Development of a Mechanism-Based Model for the Pharmacodynamics of Daptomycin against Methicillin Resistant Staphylococcus aureus (MRSA)
- The effect of surgery on the glucuronidation and sulphation of paracetamol
- Modelling red blood cell data
- Utilising prior literature population models to inform clinical practice – a dosing regimen for immediate N-acetyl cysteine treatment of paracetamol overdose
- Identification and initial evaluation of a prototype clotting time test for enoxaparin
- Antibiotic Dosing Calculator in Neonates and Children Trial
- Population Pharmacokinetics of Paracetamol in Overdose in a Single Patient
- Dexmedetomidine Hemodynamics in Children after Cardiac Surgery
- Modeling of non-stationary RBC survival: Effect of erythropoietin on RBC mortality vs. production in rats.
- Quantifying Disease Progress with Inactive Treatments in Multiple Parkinson
- Methods to Determine Optimal Sampling Windows for Nonlinear Mixed Effects Models
- Optimal designs for population pharmacokinetic studies of the partner drugs administered with artemisinin derivatives
- Development of fluconazole dosage guidelines in critically ill patients receiving continuous venovenous hemodiafiltration
- fit4NM : A tool for NONMEM users
- The use of PKPD simulations to inform the rational use of medicines in clinical practice: the case of simvastatin circadian dosing
- What is needed for a dosing calculator?
- Predicting Weight Using Postmenstrual Age
- Is Morphine Clearance Predictable in Humans?
- Missing data
- Population Pharmacokinetic-Pharmacodynamic Modeling: When Modeling Meets Reality
- Population pharmacokinetics of midazolam in critically ill septic patients
- Population pharmacokinetic and pharmacodynamics analysis of lipid emulsion propofol in pediatric patients
- Population Pharmacokinetics of Gentamicin in Saudi Newborns during the 1st Week of Life
- Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically-Ill Patients from a Multi-Center Study Provide Dosing Recommendations for Patients
- Missing data – the problem of silent evidence
- Statisticians and Pharmacometricians: What can they learn from each other?
- Population pharmacokinetics of meropenem in burn patients
- Pharmacodynamics of venlafaxine in overdose
- Identifiability of random effects parameters in mixed effects models
- Adaptive Bridging Studies in Pharmacokinetics
- Online dose calculation tool for determining dosing regimens in the very young
- Predicting the antimalarial effect of artesunate-mefloquine combination therapy using a mechanistic pharmacokinetic-pharmacodynamic model
- Optimal designs for warfarin INR monitoring
- A mathematical model for the effect of malaria on arginine catabolism in endothelial cells
- Population Pharmacokinetics of Vancomycin in Premature Malaysian Neonates: Identification of Predictors for Dosing Determination in the First Month of Life
- Evaluation of an optimal design for examining melphalan pharmacokinetics in patients with multiple myeloma
- A population PK-PD model of unbound Docetaxel in patients with liver impairment and identification of potential covariates for initial dosage adjustment
- Design of survival studies for red blood cells
- Optimal design of time-to-event models with an emphasis on dropouts in disease progression studies
- Population pharmacokinetics of total and unbound melphalan in patients with multiple myeloma
- Developing a model for estimating lean body weight in children
- Can PBPK Models Predict Post-Mortem Redistribution?
- Pharmacokinetics of Tramadol in Human Neonates, Children and Adults and in Adult Rats, Cats, Dogs, Goats and Horses
- Population pharmacokinetics of oxypurinol in patients with gout receiving allopurinol
- Optimal designs for population pharmacokinetic studies of a drug with large assay variability for patients with restrictive sampling schedules
- Novel diagnostics for assessing fit of logistic regression models
- The population pharmacokinetics of propofol: a meta-analysis of studies available from the OpenTCI Initiative
- Pharmacokinetics of Chloroquine in Pregnant and Non-pregnant Women in Papua New Guinea
- The Influence of Study Design on Identification of True Parameter-Covariate Relationships
- Risk of QTc Interval Prolongation and Torsades de Pointes (TdP) with Amisulpride
- A nonlinear mixed effects model to characterise lamivudine absorption and distribution
- The Effect of Study Design on Pharmacokinetics in Patients with Impaired Renal Function
- Does the use of Lean Body Weight (LBW) in a modified Cockcroft-Gault (C-G) equation provide a better prediction of gentamicin clearance?
- Understanding intranasal fentanyl for acute pain treatment in children: randomized controlled trials or population pharmacodynamic studies?
- Non Linear Deconvolution
- Robust D-optimal Design of Nonlinear Fixed Effects Pharmacokinetic Model
- Population pharmacokinetics of mycophenolic acid in children and young people undergoing bone marrow and solid organ transplantation
- Correlation in the absorption of lamivudine and zidovudine when administered as a fixed-dose combination tablet
- A case for routine monitoring of enoxaparin treatment
- Recirculatory Modelling of Nasal Fentanyl in Man
- Pharmacokinetics of Ethanol in the Presence of Methanol
- Population Pharmacokinetics Of Gentamicin In Very Premature Neonates
- An assessment of methods for modelling regional pharmacokinetics – pooled data, pooled parameter estimates or NONMEM?
- Mechanism-based Pharmacodynamic (PD) Modeling of Phenotypic Tolerance in Pseudomonas aeruginosa for Ceftazidime
- Lean body weight versus total body weight for propofol dosing
- A model of coagulation disturbances in snake bites
- Population pharmacokinetics of phenobarbitone administered as oral rescue therapy in children with refractory status epilepticus
- The evaluation of an individualised dosing strategy derived from population PK modelling and simulation
- Lean Body Weight as a Robust Size Descriptor for Quantifying the Impact of Body Composition on Drug Clearance
- Handling Correlated Variables
- Population pharmacokinetics of acyclovir in children with malignancy
- What to do about missing dosage history?
- Optimal design for drug interaction studies – Beyond the criss-cross design
- Modeling Diverse Anti-Diabetic Drug Effects Using Indirect Response Models: Review
- Simulation of an optimal pharmacokinetic and pharmacodynamic amikacin dosing regimen for neonates
- Mechanistic Modeling of Magnetically Marked Extended Release Formulation of Felodipine
- Handling data below the limit of quantification in mixed effect models
- When Missing Does Not Mean Lost [OED]
- Population pharmacokinetics of melphalan in myeloma patients undergoing an autograft
- Pharmacokinetics of L-arginine after intravenous infusion in adults with moderately severe malaria
- Preclinical Population PK/PD of TGF beta RI Kinase inhibitor for Cancer
- Lean Body Weight versus Total Body Weight as a Covariate for Clearance
- Normalized prediction distribution errors for the evaluation of nonlinear mixed-models
- Tobramycin in paediatric CF patients – TCI or
- Development of a sufficient design for parameter estimation of fluconazole population pharmacokinetics in HIV patients
- Population pharmacokinetic analysis of morphine in opioid dependent and control subjects
- Comparison of different diagnostic criterion to evaluate nonlinear mixed-effects models
- Optimal Designs of Studying Bioimpedance – Design for Nonlinear Mixed Effects Models
- Nonlinear Mixed Effects Modeling of the Steady-State Pharmacokinetics (PK) of Tipranavir/Ritonavir 500/200 mg bid (TPV/r) for Adult Healthy Volunteers and HIV+ Patients
- Different ways of incorporating data below the quantification limit in datasets for parameter estimation
- Population Pharmacokinetics of Amikacin in Very Premature Malaysian Neonates
- Maximum likelihood estimation in nonlinear mixed effects models with the SAEM algorithm
- Population Pharmacokinetics of Oral and Intravenous Caffeine in Extremely Premature Neonates
- Population Pharmacokinetics of Phase 1/2a Data After Oral Tablet Administration of Maraviroc
